RxDoctor Payments Data

Christyn Marshall, DPM

Primary Podiatric Medicine · Danville, CANPI 1376958405

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,136 of the $3,336 with a category attached, or 64.0%. 25 manufacturers reported payments, led by Evolution Surgical, Inc at 37.3% of the total. Reporting peaked in 2021 at $1,444 and has fallen 67.9% since, to $464 in 2025.

$3,336in general payments, 2019–2025

Across 61 payments — averaging $54.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Evolution Surgical, Inc$1K
  • Bioventus LLC$370
  • Amgen$275
  • Treace Medical Concepts, Inc.$238
  • Zimmer Biomet$227
  • Exactech, Inc.$137
  • plus $845 from 19 others

What the payments were for

  • Food & beverage$2,13664%
  • Education$1,20036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,336 in reported general payments places this provider in the 80th percentile of 59 primary podiatric medicine providers in California.

See all primary podiatric medicine providers in California

Medicare billing

Part B allowed, 2024
$138,613
Medicare patients
440
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Colchicine14$358
Meloxicam41$126
Diclofenac Sodium18$105

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Danville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →